Table 2.

Adverse events (≥20% incidence), regardless of study drug relationship, by preferred term and dose level*− dose-escalation phase (safety set)

Preferred term	Pasireotide SC, n=10
	300 µg tid n (%)	600 µg tid n (%)	900 µg tid n (%)	1200 µg tid, n (%)	All patients n (%)
Diarrhoea	4 (40)	1 (10)	0	0	5 (50)
Nausea	3 (30)	2 (20)	1 (10)	0	5 (50)
Fatigue	2 (20)	0	0	0	2 (20)
Hyperglycaemia	2 (20)	0	0	0	2 (20)
Hypophosphatemia	1 (10)	1 (10)	1 (10)	0	2 (20)
Tumour pain	2 (20)	0	0	0	2 (20)
Chills	0	1 (10)	1 (10)	0	2 (20)

*List of all AEs that started at each specific dose level. A patient with multiple occurrence of an AE preferred term in each dose level is counted only once for that preferred term.

AEs, adverse events; SC, subcutaneous; tid, three times a day.